Trial Information

The Role of Synuclein-gamma (SNCG) in the Carcinogenesis of Uterine Papillary Serous Carcinoma

OBJECTIVES:

Primary

- Determine whether synuclein-γ (SNCG) expression in primary tumor is associated with
overall survival (OS) in uterine papillary serous carcinoma (UPSC) patients.

Secondary

- Determine whether SNCG expression is associated with clinical covariates (age at
diagnosis, race, surgical stage, depth of myometrial invasion, presence of lymph
vascular space invasion, lymph node status, location of extrauterine disease,
chemotherapy, and radiation therapy) in UPSC patients.

- Determine whether SNCG expression is associated with other biomarker expression,
including TP53 (p53), HER-2, folate receptor alpha (FOLR1), estrogen receptor (ER),
progesterone receptor (PR), phosphatase and tensin homolog (PTEN), phosphorylated AKT
(pAKT), pERK, and p16 in primary tumor tissue.

- Determine whether SNCG expression is associated with progression-free survival (PFS).

- Determine whether SNCG expression is associated with synchronous or metachronous breast
cancers.

- Determine whether SNCG can be detected in sera from UPSC patients. (Exploratory)

- Determine whether serum SNCG in UPSC patients differs from that in normal healthy
control women and women with endometrioid endometrial cancer. (Exploratory)

- Determine whether serum SNCG in UPSC patients is associated with overall survival (OS),
clinical covariates (listed above), tumor expression of biomarkers (listed above), PFS,
and synchronous or metachronous breast cancers. (Exploratory)

- Develop prediction models with a panel of biomarkers and clinical prognostic factors
for OS, PFS, and synchronous or metachronous breast cancers in UPSC patients.
(Exploratory)

OUTLINE: Archived serum and tumor tissue samples are analyzed for synuclein-γ (SNCG)
expression and other biomarker expression, including TP53 (p53), HER-2, folate receptor
alpha (FOLR1), estrogen receptor (ER), progesterone receptor (PR), phosphatase and tensin
homolog (PTEN), phosphorylated AKT (pAKT), pERK, and p16 by microarray analysis, IHC assays,
and western blot. Results are then compared with patients' existing clinical, demographic,
and pathology data, including history of breast cancer (metachronous) or breast cancer
diagnosed at the same time as the endometrial cancer (synchronous).